Review Article

Therapeutic Effects and Biomarkers in Sublingual Immunotherapy: A Review

Takashi Fujimura,1 Yoshitaka Okamoto,2 and Masaru Taniguchi 1

1 Research Center for Allergy and Immunology, Yokohama Institute, RIKEN, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
2 Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohara, Chuo-ku, Chiba 260-8670, Japan

Correspondence should be addressed to Takashi Fujimura, tfujimura@rcai.riken.jp

Received 22 July 2011; Accepted 15 November 2011

Immunotherapy is considered to be the only curative treatment for allergic diseases such as pollinosis, perennial rhinitis, asthma, and food allergy. The sublingual route is widely applied for immunotherapy for allergy, instead of the conventional administration by subcutaneous route. A recent meta-analysis of sublingual immunotherapy (SLIT) has shown that this approach is safe, has positive clinical effects, and provides prolonged therapeutic effects after discontinuation of treatment. However, the mechanism of SLIT and associated biomarkers are not fully understood. Biomarkers that change after or during SLIT have been reported and may be useful for response monitoring or as prognostic indicators for SLIT. In this review, we focus on the safety, therapeutic effects, including prolonged effects after treatment, and new methods of SLIT. We also discuss response monitoring and prognostic biomarkers for SLIT. Finally, we discuss immunological mechanisms of SLIT with a focus on oral dendritic cells and facilitated antigen presentation.

1. Introduction

Allergic rhinitis is the most prevalent type I allergy, and pollen grains, mite, and mold are common causative allergens for seasonal or perennial rhinitis. Antihistamines, leukotriene inhibitors, and nasal steroids are commonly used to treat respiratory allergy, but these drugs sometimes have side effects that induce impaired performance [1, 2]. Almost 100 years have passed since the first report of immunotherapy for pollinosis in 1911 [3]. Subsequently, the protocol for allergen-specific immunotherapy has improved to increase efficacy and safety through coinjection or conjugation of allergens with an immunomodulatory adjuvant, premedication with an antihistamine or anti-human IgE antibody, or use of a rush protocol to shorten the duration of the updosing phase [4–8]. The injection route for allergens has also been examined in trials of modified allergens to shorten the schedule and to increase the safety for immunotherapy [9, 10]. In the last few decades, sublingual administration has been recognized as a route of administration of allergens that is safer than subcutaneous injection, and there is increasing evidence that the therapeutic effects of sublingual immunotherapy (SLIT) are comparable with those of traditional subcutaneous immunotherapy (SCIT) [11].

In this review, we focus on the therapeutic effects of SLIT and the problems to be solved in future clinical studies. We also discuss recent findings for prospective and response-monitoring biomarkers for SLIT, and we examine the cellular mechanisms of SLIT.

2. Safety and Therapeutic Effects of SLIT

Increasing numbers of clinical trials and meta-analyses have shown positive clinical effects and safety of SLIT. However, several case reports have also described anaphylactic shock or severe fatal reactions induced by sublingual administration of allergens [12–17]. In the reports, four patients experienced severe side effects with SCIT and discontinued the treatment.
prior to SLIT [15, 16]. Patients who have experienced severe side effects in SCIT may be at risk for a severe fatal reaction in SLIT. To prevent an allergen overdose, a tablet or solid form for sublingual administration may be better than the use of an atomizer or dispenser for administration of liquid allergens, especially for young children. Despite the few case reports of severe fatal events, life-threatening severe fatal reactions have not been found in clinical trials [18]. Therefore, SLIT is considered to be a safe treatment in which reactions such as anaphylaxis can be avoided by using correct clinical protocols.

It takes a few weeks to six months to reach a maintenance dose using SCIT with a previous updosing phase to reduce the risk of side effects [19]. In some studies, a build-up phase is used for SLIT before administering the maintenance dose of allergens. A comparison of the clinical effects and safety among four different SLIT regimes for grass pollen allergy using a mixture of extracts of five grass pollens (Anthemanthus odoratum, Dactylis glomerata, Lolium perenne, Phleum pratense, and Poa pratensis) concluded that a short build-up phase reduces the incidence of adverse events in administration of high-dose SLIT [20]. In this phase 1 study, the numbers of adverse events were compared among four active groups with a build-up phase repeating each concentration numbers of adverse events were compared among four active groups. A recent meta-analysis found positive clinical effects after an extended period of SLIT and for prolonged clinical effects after treatment [31]. SLIT in 24 children with respiratory symptoms due to monosensitization to house dust mite showed a lack of positive clinical effects in the first year, but significant amelioration of rhinitis and asthma in the second and third years compared to the first year of treatment [32]. A study of 137 patients allergic to house dust mite also showed clinical effects in 2-year and 3-year SLIT and prolonged therapeutic effects at 4 and 3 years, respectively, after these treatments [33]. Scores for nasal airway resistance, secretion, symptoms, and skin prick test were significantly reduced at the end of the first year, and the nasal secretion score was significantly reduced at the end of the second year of treatment. Two-year SLIT significantly attenuated nasal airway resistance, secretion, sneezing, symptoms, and skin prick scores at 1 and 4 years after treatment compared with the respective scores at the start of treatment although all scores except for nasal airway resistance at 4 years after treatment were slightly, but significantly, higher than those at the end of treatment. Three-year SLIT significantly attenuated these scores at the end of treatment, and total score of nasal airway resistance, secretion, and sneezing, score for the nasal airway resistance, and symptom score at 3 years after treatment were similar to or lower than those at the end of treatment.

Carry-over effects of SLIT are supported by other studies. DBPC trials of 3-year SLIT for grass pollen allergy showed significantly decreased scores for symptom and the rhino-conjunctivitis quality-of-life questionnaire (RQLQ), and SMS and the medication score tended to decrease with active treatment compared with those for placebo at 1 year after SLIT [34, 35]. Our recent results also suggest a 1-year prolongation of clinical effects after 2-year SLIT for Japanese cedar pollinosis [36]. Analysis of 88 participants (SLIT; N = 51, placebo; N = 37) showed positive therapeutic effects in the second year of SLIT compared with placebo (reduction of SMS by 21%, P = 0.02) and at 1 year after treatment (23%, P = 0.03) (Figure 1). A recent phase III trial performed as
a large-scale randomized, DBPC study using a 75,000 SQ-T/2,800 BAU tablet in 257 subjects allergic to grass pollen also has shown that 3-year SLIT significantly decreased the mean rhinoconjunctivitis symptom and medication scores at 1 year after treatment compared with placebo. The results showed reductions of symptom scores of 31%, 36%, 29%, and 26% and reductions of medication scores of 38%, 45%, 40%, and 29% after 1, 2, and 3 years of treatment and after a follow-up year, respectively [37]. Long-lasting effects after 3-, 4-, and 5-year SLIT were evaluated in a 15-year prospective open controlled study in 59 patients with respiratory allergy for mite [38]. A decreased SMS of <50% of the baseline score (at the start of treatment) was found over the following 6 years after 3-year SLIT, and over 8 years after 4- and 5-year SLIT. The SMS after loss of the prolonged therapeutic effects increased to levels comparable with those in the control group. Significant clinical effects were obtained in a second course of SLIT given after the initial effects had vanished.

### 3. Unmet Problems in SLIT

Compliance with self-administration at home may be an important factor in the therapeutic effect of SLIT. Compliance with SLIT is likely to be similar to that for other self-administered drug treatments for allergy [11], and education on the SLIT protocol is needed for good compliance [39, 40]. Checking the compliance of each patient based on the amount of remaining vials or tablets may also be important for evaluating the efficacy of SLIT in clinical trials [34]. A device that reminds patients about intake of allergens may be useful to achieve good compliance in long term administration and to improve the efficacy of SLIT [41]. Delivery as a tablet or solid form may be better than an aqueous solution using an atomizer or dispenser to achieve good compliance and to hold allergens stably under the tongue because human error or bad conditions of a nozzle may lead to administration of an inaccurate amount of liquid drops. Such mistakes may also increase the risk of adverse reactions [17].

Bystander therapeutic effects of SLIT using allergens from a single source with polysensitized patients are uncertain. Inferior therapeutic effects for a polysensitized population have been reported compared with a monosensitized population [42]. Recent findings have shown that the use of both single and mixed allergen extracts improved mean QOL scores, increased threshold of a titrated nasal challenge, and decreased skin prick tests reactivity in polysensitized patients [43–45]. The efficacy of SLIT for polysensitized patients has also been found to be comparable with that for monosensitized patients [28]. Furthermore, SLIT for monosensitized (rhinitis only) and polysensitized (rhinitis and asthma) patients prevented or reduced additional sensitization compared with drug treatment [46, 47]. These preventive effects of SLIT were clearer for monosensitized patients. In contrast, SLIT for birch pollinosis was not effective against an already established apple allergy [48]. Mal d 1, a major allergen in apple, has 64% identity in amino acid sequence with Bet v 1, a major allergen in birch, and these allergens are cross-reactive in IgE-binding and T-cell activation. Bystander effects of SLIT using allergens from a single source for patients with other established allergies may depend on the allergens used for immunotherapy and the degree of sensitization to the allergy. Further clinical trials and meta-analyses are needed to evaluate the bystander and prophylactic effects of SLIT.

In 2010, the World Allergy Organization defined a systemic reaction grading system for scoring of adverse reactions by SCIT to enable comparison of the severity of adverse events among clinical trials [49]. A similar approach to evaluation of clinical effects and adverse events in SLIT is needed to compare the clinical effects and therapeutic efficacy among studies that differ in allergen, dose, and method and protocol of administration. This will permit improved meta-analyses. Currently, it is difficult to optimize the SLIT protocol using results from multiple clinical trials that used different methods for evaluation of therapeutic effects, such as cumulative or average scores for symptoms and
medication, QOL, VAS, local symptoms, and days with mild or severe symptoms over periods of days, months, seasons, and years [18, 50, 51]. It will be difficult to score the severity of allergic symptoms using the same grading system because both the pattern and main organ in which symptoms appear may differ among seasonal or perennial allergies in various areas. However, a scoring or grading system for use in scientific reports is needed as a minimum requirement to permit improved understanding by readers.

4. Trials of Adjuvant Therapy with SLIT

Coadministration of an adjuvant with allergens may achieve more efficient and effective SLIT. Many studies in mouse models of asthma or rhinitis have shown increased effects of SLIT with adjuvant therapy. In most cases, the adjuvant is used to enhance development or activation of regulatory T cells (Treg) or increase adherence or permeability of allergens in sublingual mucosa to enhance uptake by antigen-presenting cells (APCs) such as mucosal dendritic cells (DC). Sublingual administration of an antigen conjugated with the nontoxic B subunit of cholera toxin to mice significantly induced antigen-specific Foxp3+CD4+ T cells in cervical lymph nodes and spleen and suppressed proliferation of cells from cervical lymph nodes after stimulation with antigen to a greater extent than that after treatment with the unmodified antigen. The serum TGF-β level was also higher after administration of the modified antigen compared to the unmodified antigen [52]. Sublingual coadministration of an antigen with either 1,25-dihydroxyvitamin D3 plus dexamethasone (VitD3/DEX) or Lactobacillus plantarum suppressed airway hyperresponsiveness (measured as PenH) compared with antigen alone, and coadministration with VitD3/DEX significantly induced Foxp3+CD4+ T cells in mice [53]. Another mouse study supported the adjuvant activity of lactic acid bacteria in enhancing the therapeutic effects of SLIT [54]. A study using polymerized carbohydrate as a mucoadhesive adjuvant showed superior reduction of established airway hyperresponsiveness (PenH) and lung inflammation compared to administration of antigen alone or phosphate-buffered saline [55]. In this study, IL5 and IL10 production from splenocytes was reduced after stimulation with antigen in mice-administered antigen with adjuvant compared with mice-administered PBS or antigen alone. The therapeutic effects of adjuvant SLIT are also under evaluation in humans. In a Phase I/IIa study, coadministration of grass allergens with a high dose of monophosphoryl lipid A, an agonist for toll-like receptor 4, significantly increased the rate of negative findings in a nasal challenge test at two weeks after completion of 8-week treatment [56]. Further large scale studies are needed to evaluate the efficacy of adjuvant SLIT in humans.

5. Recent Findings on Biomarkers for SLIT

Candidate biomarkers for response-monitoring or prognosis have been proposed and evaluated in many studies [4, 57, 58]. IL10 and Treg cells appear to be involved in the therapeutic mechanism of SLIT [59–61]. We reported upregulation of antigen-specific Treg cells (IL10+Foxp3+ cells) in CD25+CD4+ leukocytes from pre- to postpollen season as a response-monitoring biomarker for SLIT [36, 62]. Among patients treated with SLIT, total QOL and QOL-symptom scores after 2 years of treatment significantly improved in a subgroup with increased Treg cells compared with the placebo group, whereas the scores in a subgroup with decreased Treg cells were similar to those in the placebo group (Figure 2(a)). We also proposed that the ratio of antigen-specific IgE to total IgE (sIgE/tIgE) was a candidate as a prognostic biomarker for SLIT in a DBPC trial [36]. SMS in the SLIT group was correlated with the sIgE/tIgE ratio before treatment and was significantly improved in patients with a low sIgE/tIgE ratio compared to that in patients with a high sIgE/tIgE ratio (Figures 2(b) and 2(c)) [36]. The sIgE/tIgE ratio has been found to be significantly higher in responders than in nonresponders following 4-year im-munotherapy [63]. In this study, responders to the immunotherapy (42 patients for SCIT and 103 patients for SLIT) showed higher grass- or mite-specific IgE/tIgE ratio than nonresponders (34 patients for SCIT and 100 patients for SLIT) evaluated with VAS score. In our trial, this ratio did not differ significantly between responders and nonresponders [36]. Further validation studies with a large sample size are needed before these biomarkers can be applied in the clinical management of SLIT.

Upregulation of regulatory molecules after SLIT has been reported [57, 64] and programmed cell death ligand 1 (PD1L), IL10, and IgG4 may serve as response-monitoring biomarkers for SLIT [65]. In this report, all patients who received preseasonal, seasonal, and prolonged SLIT had increased percentages of PD1L+ and IL10+PD1L+ cells among CD14+ and CD19+ cells after stimulation with antigen in pollen season, compared to a placebo group. PD1L is involved in induction and maintenance of Foxp3+CD4+ Treg cells in the presence of TGFβ in mouse [66, 67], and induction of PD1L may play an important role in induction of Treg cells by SLIT.

Apoprotein is involved in lipid metabolism and lipid transport, and apoprotein E has roles in lipid antigen presentation and inhibition of T-cell activation [68, 69]. Upregulation of apoprotein A-IV (ApoA-IV) in serum in pollinosis patients from pre- to postpollen season was found to be significantly greater with SLIT than with placebo and was inversely correlated with SMS and QOL scores in the SLIT group [70]. ApoA-IV also significantly reduces histamine release in vitro from basophils taken from patients [70], and ApoA-IV induced by SLIT may be involved in downregulation of local or peripheral inflammation during the pollen season.

6. Mechanisms of SLIT

Treg cells play an important role in suppression of Th2 responses and inflammatory cells [4, 71]. However, the cells that induce Treg cells after sublingual administration of allergens and the mechanism of induction remain unclear. DCs that preferentially induce Treg cells are thought to be located in the sublingual mucosa. In a mouse study, three types of DCs with different surface markers were identified.
within lingual and buccal tissue: CD207+ Langerhans cells in the mucosa, CD11b+CD11c− and CD11b+CD11c+ myeloid DCs at the mucosal/submucosal interface, and B220+120G8+ plasmacytoid DCs [72]. Oral CD11b+CD11c− DCs induced IFN-γ production by T cells, and oral CD11b+CD11c+ DCs and B220+120G8+ DCs induced IFN-γ and IL10 production by T cells in an antigen-specific manner. These oral DCs may preferentially skew development to antigen specific Th1 or Treg. The function of CD207+ Langerhans cells could not be determined because of limited cell numbers. In humans, oral mucosal Langerhans cells (oLCs) that constitutively express FceRI on the surface have been found in atopic and nonatopic subjects [73]. Expression levels of FceRI were found to be significantly correlated with serum IgE levels in atopic subjects. oLCs also expressed significantly higher amounts of major histocompatibility complex (MHC) I and II, CD40, CD80, and CD86 compared to skin Langerhans cells [73]. Toll-like receptor 4-ligation of oLCs has also been shown to induce production of IL10, TGF-β, IL2, IFN-γ, and Foxp3 [74], and oLCs might capture allergens within sublingual mucosa and present them to T cells to develop antigen-specific Treg cells [75, 76]. Further studies are needed to determine the importance of oral DCs and oLCs in the therapeutic mechanisms of SLIT.
Induction of IgG and IgG4 as blocking antibodies in SLIT is still under debate [77, 78]. IgE enhances uptake and presentation of invading antigens by APCs via CD23, a process known as facilitated antigen presentation (FAP), and transcytosis by human airway epithelial cells in a CD23-dependent manner [79, 80]. The immune complex of IgE with antigen binds to CD23, and this binding leads to enhance antigen presentation by APCs to T cells [79]. There is increasing evidence to show that SLIT inhibits FAP by preventing binding of IgE with antigen or CD23 [81]. Decreased FAP after immunotherapy is correlated with T-cell activation in vitro and antigen-specific IgG titer, and FAP activity tends to correlate with IgE/IgG4 ratio and symptom score [82–84]. This inhibition of FAP leads to decrease antigen-specific proliferation and IL4, IL5, IL10, and IFN-γ production from T cells [85]. The inhibition persists over 2 years after discontinuation of 2-year immunotherapy although specific IgG and IgG4 levels decreased to preimmunotherapy levels [86]. Other factors may also be involved in the mechanism of FAP by inhibiting CD23 and IgE binding.

7. Conclusions

One of the aims of immunotherapy is to induce tolerance against invading allergens. The therapeutic effects and efficacy of SLIT vary among allergies with different causal allergen sources. Achievement of a level of tolerance at which drugs are not required and symptoms are absent in the greatest numbers of patients requires further optimization of protocols and modification of SLIT or standardization of allergens as a SLIT vaccine. Adjuvant SLIT and combination with other methods may help to achieve more effective SLIT. The involvement of oral DC, oLCs, Treg, and FAP in the therapeutic mechanisms of SLIT has been proposed in many studies in humans and in mice (Figure 3). To determine the chain of mechanisms of SLIT, more studies are needed using human materials from clinical trials with large sample numbers. Understanding the precise mechanisms of SLIT should facilitate more effective immunotherapy for more patients with allergies.

Abbreviations

APC: antigen-presenting cells
DBPC: double-blind, placebo-controlled
DC: dendritic cells
SCIT: subcutaneous immunotherapy
SLIT: sublingual immunotherapy
SMD: standardized mean difference
SMS: symptom-medication score
Treg: regulatory T cells
QOL: quality-of-life
VAS: Visual Analog Scale.

References

[1] I. Jáuregui, J. Mullol, I. Dávila et al., “Allergic rhinitis and school performance,” Journal of Investigational Allergology
and Clinical Immunology, vol. 19, supplement 1, pp. 32–39, 2009.

[2] S. Walker, S. Khan–Wasti, M. Fletcher, P. Cullinan, J. Harris, and A. Sheikh, “Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case–control study,” Journal of Allergy and Clinical Immunology, vol. 120, no. 2, pp. 381–387, 2007.

[3] L. Noon, “Prophylactic inoculation against hay fever,” The Lancet, vol. 177, no. 4580, pp. 1572–1573, 1911.

[4] M. Larché, C. A. Akdis, and R. Valenta, “Immunological mechanisms of allergen-specific immunotherapy,” Nature Reviews Immunology, vol. 6, no. 10, pp. 761–771, 2006.

[5] P. L. Bhalla and M. B. Singh, “Biotechnology-based allergy diagnosis and vaccination,” Trends in Biotechnology, vol. 26, no. 3, pp. 153–161, 2008.

[6] U. Müller, Y. Hari, and E. Berchtold, “Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy,” Journal of Allergy and Clinical Immunology, vol. 107, no. 1, pp. 81–86, 2001.

[7] J. Kuehr, J. Brauburger, S. Zielen et al., “Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis,” Journal of Allergy and Clinical Immunology, vol. 109, no. 2, pp. 274–280, 2002.

[8] S. Klunker, L. R. Saggar, V. Seyfert-Margolis et al., “Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: inhibition of IgE-facilitated allergen binding,” Journal of Allergy and Clinical Immunology, vol. 120, no. 3, pp. 688–695, 2007.

[9] G. W. Canonica and G. Passalacqua, “Noninjection routes for immunotherapy,” Journal of Allergy and Clinical Immunology, vol. 111, no. 3, pp. 437–448, 2003.

[10] G. Senti, B. M. Prinz Varvicka, I. Erdmann et al., “Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 46, pp. 17908–17912, 2008.

[11] C. Incorvaia, S. Masieri, S. Scurati, S. Sozzani, and F. Frati, “The current role of sublingual immunotherapy in the treatment of allergic rhinitis in adults and children,” Journal of Asthma and Allergy, no. 4, pp. 13–17, 2011.

[12] A. Antico, M. Pagani, and A. Crema, “Anaphylaxis by latex sublingual immunotherapy,” Allergy, vol. 61, no. 10, pp. 1236–1237, 2006.

[13] E. H. Dunsky, M. F. Goldstein, D. J. Dvorin, and G. A. Belecanech, “Anaphylaxis to sublingual immunotherapy,” Allergy, vol. 61, no. 10, pp. 1235, 2006.

[14] A. O. Eifan, S. Keles, N. N. Bahceciler, and I. B. Barlan, “Anaphylaxis to multiple pollen allergen sublingual immunotherapy,” Allergy, vol. 62, no. 5, pp. 567–568, 2007.

[15] H. De Groot and A. Bijl, “Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet,” Allergy, vol. 64, no. 6, pp. 963–964, 2009.

[16] M. M. Coehard and P. A. Eigenmann, “Sublingual immunotherapy is not always a safe alternative to subcutaneous immunotherapy,” Journal of Allergy and Clinical Immunology, vol. 124, no. 2, pp. 378–379, 2009.

[17] L. Blazewska, “Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose,” Allergy, vol. 63, no. 3, p. 374, 2008.

[18] S. Radulovic, D. Wilson, M. Calderon, and S. Durham, “Systematic reviews of sublingual immunotherapy (SLIT),” Allergy, vol. 66, no. 6, pp. 740–752, 2011.

[19] L. Cox, J. T. Li, and H. Nelson, “Allergen immunotherapy: a practice parameter second update,” Journal of Allergy and Clinical Immunology, vol. 120, supplement 3, pp. S25–S85, 2007.

[20] T. H. Larsen, L. K. Poulsen, M. Melac, A. Combebias, C. Andre, and H. J. Malling, “Safety and tolerability of grass pollen tablets in sublingual immunotherapy—a phase-1 study,” Allergy, vol. 61, no. 10, pp. 1173–1176, 2006.

[21] D. Passali, R. Mösge, G. C. Passali, F. M. Passali, G. Ayoko, and L. Bellussi, “Safety, tolerability and efficacy of sublingual allergoid immunotherapy with three different shortened updosing administration schedules,” Acta Otorhinolaryngologica Italica, vol. 30, no. 3, pp. 131–137, 2010.

[22] J. Stelmach, J. Kaczmarek-Wozniak, P. Majak, M. Olszowiec-Chlebna, and J. Jerzynska, “Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen,” Clinical and Experimental Allergy, vol. 39, no. 3, pp. 401–408, 2009.

[23] J. Seidenberg, G. B. Pajno, C. P. Bauer, S. La Grutta, and J. Sieber, “Safety and tolerability of seasonal ultra-rush, high-dose sublingual-swell immunotherapy in allergic rhinitis to grass and tree pollens: an observational study in 193 children and adolescents,” Journal of Investigational Allergology and Clinical Immunology, vol. 19, no. 2, pp. 125–131, 2009.

[24] R. E. Rossi, G. Monasterolo, G. Coco, and D. Operti, “Possible relationship between systemic side effects and sensitization to rPar1 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis,” International Archives of Allergy and Immunology, vol. 138, no. 2, pp. 105–110, 2005.

[25] F. Rodriguez, M. Boquete, M. D. Ibáñez, F. De La Torre-Martínez, and A. I. Tabar, “Once daily sublingual immunotherapy without updosing—a new treatment schedule,” International Archives of Allergy and Immunology, vol. 140, no. 4, pp. 321–326, 2006.

[26] D. Di Bona, A. Plaia, V. Scafidi, M. S. Leto-Barone, and G. Di Lorenzo, “Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis,” Journal of Allergy and Clinical Immunology, vol. 126, no. 3, pp. 558–566, 2010.

[27] M. S. Khinchin, L. K. Poulsen, F. Carat, C. André, A. B. Hansen, and H. J. Malling, “Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double dummy study,” Allergy, vol. 59, no. 1, pp. 45–53, 2004.

[28] S. R. Durham, “Sublingual immunotherapy: What have we learnt from the ‘big trials’?” Current Opinion in Allergy and Clinical Immunology, vol. 8, no. 6, pp. 577–584, 2008.

[29] M. T. Ventura, A. Carretta, R. A. Tummino, R. Buquicchio, A. Arsiemi, and N. Murgia, “Clinical data and inflammation parameters in patients with cypress allergy treated with sublingual swallow therapy and subcutaneous immunotherapy,” International Journal of Immunopathology and Pharmacology, vol. 22, no. 2, pp. 403–413, 2009.

[30] S. Keles, E. Karakoc-Aydiner, A. Ozcn et al., “A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes,” Journal of Allergy and Clinical Immunology, vol. 128, no. 4, pp. 808–815.e7, 2011.

[31] P. Panzer, M. Petráš, T. Šykora, I. K. Lesná, and M. Liška, “Both sublingual and supralingual routes of administration are effective in long-term allergen-specific immunotherapy,” Allergy and Asthma Proceedings, vol. 32, no. 2, pp. 142–150, 2011.
S. Piconi, D. Trabattoni, V. Rainone et al., “Immunological...tolerance, and immune deviation,” *Journal of Allergy and Clinical Immunology*, vol. 120, no. 3, pp. 707–713, 2007.

T. Fujimura, S. Yonekura, Y. Taniguchi et al., “The induced regulatory T cell level, defined as the proportion of IL-10-Foxp3^+^ cells among CD25^+^CD4^+^ cells, is a potential therapeutic biomarker for sublingual immunotherapy: a preliminary report,” *International Archives of Allergy and Immunology*, vol. 153, no. 4, pp. 378–387, 2010.

G. Di Lorenzo, P. Mansueto, M. L. Pacor et al., “Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy,” *Journal of Allergy and Clinical Immunology*, vol. 123, no. 5, pp. 1103–1110.e4, 2009.

N. Novak, T. Bieber, and J.-P. Allam, “Immunological mechanisms of sublingual allergen-specific immunotherapy,” *Allergy*, vol. 66, no. 6, pp. 733–739, 2011.

S. Piconi, D. Trabattoni, V. Rainone et al., “Immunological effects of sublingual immunotherapy: clinical efficacy is associated with modulation of programmed cell death ligand 1, IL-10, and IgG4,” *Journal of Immunology*, vol. 185, no. 12, pp. 7723–7730, 2010.

L. Wang, K. Pino-Lagos, V. C. De Vries, I. Guleria, M. H. Sayegh, and R. J. Noelle, “Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3^+^CD4^+^ regulatory T cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 27, pp. 9331–9336, 2008.

L. M. Francisco, V. H. Salinas, K. E. Brown et al., “PD-L1 regulates the development, maintenance, and function of induced regulatory T cells,” *Journal of Experimental Medicine*, vol. 206, no. 13, pp. 3015–3029, 2009.

P. Van Den Elzen, S. Garg, L. León et al., “Apolipoprotein-mediated pathways of lipid antigen presentation,” *Nature*, vol. 437, no. 7060, pp. 906–910, 2005.

C. Tenger and X. Zhou, “Apolipoprotein E modulates immune activation by acting on the antigen-presenting cell,” *Immunology*, vol. 109, no. 3, pp. 392–397, 2003.

Y. Makino, E. Noguchi, N. Takahashi et al., “Apolipoprotein A-IV is a candidate target molecule for the treatment of seasonal allergic rhinitis,” *Journal of Allergy and Clinical Immunology*, vol. 126, no. 6, pp. 1126–1130.e1, 2010.

T. Akkoc, M. Akdis, and C. A. Akdis, “Update in the mechanisms of allergen-specific immunotherapy,” *Allergy, Asthma and Immunology Research*, vol. 3, no. 1, pp. 11–20, 2010.

L. Mascarel, V. Lombardi, A. Louise et al., “Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4^+^ T cells,” *Journal of Allergy and Clinical Immunology*, vol. 122, no. 3, pp. 603–609.e5, 2008.

J. P. Allam, N. Novak, C. Fuchs et al., “Characterization of dendritic cells from human oral mucosa: a new Langerhans cell type with high constitutive FcRI expression,” *Journal of Allergy and Clinical Immunology*, vol. 112, no. 1, pp. 141–148, 2003.

J. P. Allam, W. M. Peng, T. Appel et al., “Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells,” *Journal of Allergy and Clinical Immunology*, vol. 121, no. 2, pp. 368–374.e1, 2008.

J. P. Allam, P. A. Würtzen, M. Reinartz et al., “Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-β1 and IL-10-producing properties,” *Journal of Allergy and Clinical Immunology*, vol. 126, no. 3, pp. 638–645.e1, 2010.

M. Larché, “Immune mechanisms of sublingual immunotherapy: are oral Langerhans cells the masters of tolerance?” *Journal of Allergy and Clinical Immunology*, vol. 126, no. 3, pp. 646–647, 2010.

P. A. Wachholz and S. R. Durham, “Induction of ‘blocking’ IgG antibodies during immunotherapy,” *Clinical and Experimental Allergy*, vol. 33, no. 9, pp. 1171–1174, 2003.

M. Akdis and C. A. Akdis, “Mechanisms of allergen-specific immunotherapy,” *Clinical and Experimental Allergy*, vol. 119, no. 4, pp. 780–789, 2007.

F. L. Van der Heijden, R. I. Joost van Neerven, M. Van Katwijk, J. D. Bos, and M. L. Kapsenberg, “Serum-IgE-facilitated allergen presentation in atopic disease,” *Journal of Immunology*, vol. 150, no. 8, pp. 3643–3650, 1993.

S. Palanijandi, E. Tomei, Z. Li, D. H. Conrad, and X. Zhu, “CD23-dependent transcytosis of IgE and immune complex across the polarized human respiratory epithelial cells,” *Journal of Immunology*, vol. 186, no. 6, pp. 3484–3496, 2011.

G. W. Scadding, M. H. Shamji, M. R. Jacobson et al., “Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells,” *Clinical and Experimental Allergy*, vol. 40, no. 4, pp. 598–606, 2010.

P. A. Wührten, G. Lund, K. Lund, M. Arvidsson, S. Rak, and H. Ipsen, “A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation,” *Clinical and Experimental Allergy*, vol. 38, no. 8, pp. 1290–1301, 2008.

I. Pree, M. H. Shamji, I. Kimber, R. Valenta, S. R. Durham, and V. Niederberger, “Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules,” *Clinical and Experimental Allergy*, vol. 40, no. 9, pp. 1346–1352, 2010.

R. J. J. Van Neerven, M. Arvidsson, H. Ipsen, S. H. Sparholt, S. Rak, and P. A. Würtzen, “A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin G-facilitated allergen presentation,” *Clinical and Experimental Allergy*, vol. 34, no. 3, pp. 420–428, 2004.

R. J. J. Van Neerven, T. Wikborg, G. Lund et al., “Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4^+^ T cells by inhibiting serum-IgE-facilitated allergen presentation,” *Journal of Immunology*, vol. 163, no. 5, pp. 2944–2952, 1999.

L. K. James, M. H. Shamji, S. M. Walker et al., “Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies,” *Journal of Allergy and Clinical Immunology*, vol. 127, no. 2, pp. 509–516.e5, 2011.